These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26469965)

  • 1. Heart disease: recruitment of MEF2 activity by β-blockers wards off cardiomyocyte death.
    Hashemi S; Wales S; Miyake T; McDermott JC
    Cell Death Dis; 2015 Oct; 6(10):e1916. PubMed ID: 26469965
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta
    Steinberg SF
    Circ Res; 2018 Nov; 123(11):1199-1201. PubMed ID: 30571467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs used in heart disease. 1. Pharmacology--1.
    Landowski R; Shulman R; Davies R
    Nurs Times; 2002 Apr 30-May 6; 98(18):43-6. PubMed ID: 12035447
    [No Abstract]   [Full Text] [Related]  

  • 4. Heart Failure and MEF2 Transcriptome Dynamics in Response to β-Blockers.
    Tobin SW; Hashemi S; Dadson K; Turdi S; Ebrahimian K; Zhao J; Sweeney G; Grigull J; McDermott JC
    Sci Rep; 2017 Jun; 7(1):4476. PubMed ID: 28667250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs used in heart disease. 3. Applications.
    Shulman R; Davies R; Landowski R
    Nurs Times; 2002 May 14-20; 98(20):43-6. PubMed ID: 12168400
    [No Abstract]   [Full Text] [Related]  

  • 6. Three Generations of β-blockers: History, Class Differences and Clinical Applicability.
    do Vale GT; Ceron CS; Gonzaga NA; Simplicio JA; Padovan JC
    Curr Hypertens Rev; 2019; 15(1):22-31. PubMed ID: 30227820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta blockers as cardioprotective agents: Part I--Insights into mechanisms of action.
    Frishman WH
    Am J Manag Care; 2002 Jun; 8(9 Suppl):13-7. PubMed ID: 12099323
    [No Abstract]   [Full Text] [Related]  

  • 8. Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility.
    Wang Q; Wang Y; West TM; Liu Y; Reddy GR; Barbagallo F; Xu B; Shi Q; Deng B; Wei W; Xiang YK
    Cardiovasc Res; 2021 Aug; 117(10):2237-2251. PubMed ID: 32956449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blocker-induced heart rate lowering, cardioprotection, and hypertension.
    Khan SS
    J Am Coll Cardiol; 2009 Jun; 53(22):2104-5; author reply 2106-7. PubMed ID: 19477368
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardioprotective effects of the Ιf current inhibition by ivabradine during cardiac dysfunction.
    Su JB
    Curr Pharm Biotechnol; 2014; 14(14):1213-9. PubMed ID: 24831809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Β-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells.
    Chimenti I; Pagano F; Cavarretta E; Angelini F; Peruzzi M; Barretta A; Greco E; De Falco E; Marullo AG; Sciarretta S; Biondi-Zoccai G; Frati G
    Sci Rep; 2016 Nov; 6():36774. PubMed ID: 27841293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pycnogenol increases the probability of the contraction state in chick embryonic cardiomyocytes, indicating inotropic effects.
    Hasegawa N; Kinoshita H; Mochizuki M
    Phytother Res; 2007 Feb; 21(2):181-2. PubMed ID: 17078108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioprotection: the role of beta-blocker therapy.
    Egan BM; Basile J; Chilton RJ; Cohen JD
    J Clin Hypertens (Greenwich); 2005 Jul; 7(7):409-16. PubMed ID: 16015051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure.
    Berger R; Moertl D; Huelsmann M; Bojic A; Ahmadi R; Heissenberger I; Pacher R
    Eur J Heart Fail; 2007 Feb; 9(2):202-8. PubMed ID: 16859992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction.
    Ahmet I; Krawczyk M; Zhu W; Woo AY; Morrell C; Poosala S; Xiao RP; Lakatta EG; Talan MI
    J Pharmacol Exp Ther; 2008 May; 325(2):491-9. PubMed ID: 18287209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expert Consensus document on beta-adrenergic receptor blockers].
    López-Sendón J; Swedberg K; McMurray J; Tamargo J; Maggioni AP; Dargie H; Tendera M; Waagstein F; Kjekshus J; Lechat P; Torp-Pedersen C;
    Rev Esp Cardiol; 2005 Jan; 58(1):65-90. PubMed ID: 15680133
    [No Abstract]   [Full Text] [Related]  

  • 17. Patient-specific induced pluripotent stem-cell models for long-QT syndrome.
    Moretti A; Bellin M; Welling A; Jung CB; Lam JT; Bott-Flügel L; Dorn T; Goedel A; Höhnke C; Hofmann F; Seyfarth M; Sinnecker D; Schömig A; Laugwitz KL
    N Engl J Med; 2010 Oct; 363(15):1397-409. PubMed ID: 20660394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse cardiovascular drug interactions.
    Opie LH
    Curr Probl Cardiol; 2000 Sep; 25(9):621-76. PubMed ID: 11043147
    [No Abstract]   [Full Text] [Related]  

  • 19. Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers.
    Barbosa RR; Bourguignon TB; Torres LD; Arruda LS; Jacques TM; Serpa RG; Calil OA; Barbosa LFM
    Rev Assoc Med Bras (1992); 2018 Aug; 64(8):745-754. PubMed ID: 30673046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure.
    Packer M
    J Am Heart Assoc; 2020 Aug; 9(16):e016270. PubMed ID: 32791029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.